NCT04031742View on ClinicalTrials.gov

A Study to Evaluate Safety and Efficacy of IBI306, a PCSK9 Monoclonal Antibody in Chinese Subjects With Homozygous Familial Hypercholesterolemia

PHASE2/PHASE3CompletedINTERVENTIONAL

Enrollment

Participants

Timeline

Start Date

September 29, 2019

Primary Completion Date

December 30, 2021

Study Completion Date

December 30, 2021

Conditions

Homozygous Familial Hypercholesterolemia

Interventions

BIOLOGICAL

IBI306

Administered by subcutaneous injection

BIOLOGICAL

IBI306

Administered by subcutaneous injection

Trial Locations (1)

Unknown

Beijing Anzhen Hospital, Capital Medical University, Beijing

All Listed Sponsors

lead

Innovent Biologics (Suzhou) Co. Ltd.

INDUSTRY

NCT04031742 - A Study to Evaluate Safety and Efficacy of IBI306, a PCSK9 Monoclonal Antibody in Chinese Subjects With Homozygous Familial Hypercholesterolemia | Biotech Hunter | Biotech Hunter